UTHR Beats Q4 Earnings Expectations, Stock Jumps 13% Following Robust Outlook

United Therapeutics Surpasses Q4 2025 Earnings Expectations

United Therapeutics (UTHR) posted fourth-quarter 2025 earnings per share of $7.70, outperforming the Zacks Consensus Estimate of $6.78. This marks a 24% increase from the previous year, largely fueled by stronger product sales.

Product Portfolio and Market Presence

The company offers four treatments for pulmonary arterial hypertension (PAH): Tyvaso, Orenitram, Adcirca, and Remodulin. Additionally, Unituxin is marketed for children with high-risk neuroblastoma.

Quarterly Revenue Performance

Fourth-quarter revenue reached $790.2 million, falling short of the expected $805 million, but still reflecting a 7.3% year-over-year rise. This growth was mainly attributed to robust sales of Tyvaso and Orenitram.

Despite mixed quarterly results, United Therapeutics’ stock climbed 13% on Wednesday after the company shared an optimistic outlook for the coming years. Management anticipates “double-digit revenue growth” in 2026, and projects an annualized revenue run rate of $4 billion in the latter half of 2027.

Over the past year, United Therapeutics’ shares have surged 68.4%, significantly outpacing the industry’s 3.9% gain.

Detailed Breakdown of Q4 Results

Tyvaso remains a primary revenue driver, with both its dry powder inhalation (DPI) and nebulized forms approved for PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD).

• Total Tyvaso sales reached $464.3 million, up 12% year over year, though slightly below the $488 million consensus estimate.
• Tyvaso DPI brought in $338.6 million, a 24% increase, supported by enhanced commercialization and Medicare Part D changes under the Inflation Reduction Act, which boosted patient access.
• Nebulized Tyvaso revenue was $125.7 million, down 12% due to lower volumes.
• Orenitram sales rose 12% to $121.2 million, driven by higher demand and improved marketing.
• Remodulin (including Remunity Pump) sales declined 5% to $128 million.
• Unituxin sales dropped 8% to $62.3 million.
• Adcirca sales jumped 66% to $7.8 million.

Research and development expenses increased 4.3% to $139.5 million, reflecting higher clinical trial costs and greater share-based compensation. Selling, general, and administrative expenses rose 13.1% to $190.6 million, mainly due to higher consulting and personnel costs.

As of December 31, 2025, United Therapeutics held $4.6 billion in cash, cash equivalents, and investments, up from $4.3 billion at the end of September 2025, and remained debt-free.

Full-Year 2025 Financial Highlights

For the full year, United Therapeutics generated $3.18 billion in revenue, an 11% increase over the prior year. Net earnings per share for 2025 were $27.86, up from $24.64 in 2024.

Pipeline Developments and Recent Updates

The company’s late-stage pipeline includes phase III studies of Tyvaso for various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral ralinepag for PAH (ADVANCE OUTCOMES study).

In September 2025, results from the TETON-2 trial demonstrated clinical benefits for idiopathic pulmonary fibrosis (IPF) patients treated with nebulized Tyvaso over a year, meeting both primary and key secondary endpoints. Management believes these findings could expand Tyvaso’s use.

United Therapeutics is also conducting the TETON-1 phase III trial in IPF, with results expected in the first half of 2026. The company plans to engage with the FDA to potentially accelerate regulatory review once data are available. If approved for IPF, Tyvaso sales in this indication could surpass those for PAH. Enrollment is ongoing for the TETON PPF study in progressive pulmonary fibrosis.

The phase III ADVANCE OUTCOMES trial for ralinepag in PAH is also underway, with top-line results anticipated in the first half of 2026.

Stock Performance and Analyst Ratings

Currently, United Therapeutics holds a Zacks Rank #4 (Sell).

Other biotech stocks with stronger Zacks rankings include:

• Castle Biosciences (CSTL) – Zacks Rank #1 (Strong Buy)
• ANI Pharmaceuticals (ANIP) – Zacks Rank #2 (Buy)
• Assertio Holdings (ASRT) – Zacks Rank #2 (Buy)

Castle Biosciences’ projected 2026 loss per share has improved from $1.06 to $0.96 over the past 60 days, and its shares have climbed 18.4% in the past year. The company exceeded earnings estimates in three of the last four quarters, with an average surprise of 66.11%.

Assertio’s estimated 2026 loss per share narrowed from $0.30 to $0.28 in the last two months, with shares up 1% over the past year. Assertio beat earnings estimates in one of the past four quarters, with an average negative surprise of 35.21%.

ANI Pharmaceuticals’ 2026 earnings per share estimate increased from $8.08 to $8.22 in the past 60 days. Its shares have surged 38.7% over the last year, and the company beat earnings estimates in all four recent quarters, averaging a 21.24% surprise.